Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), is pleased to
announce that it has launched its Leefylyfe™ brand of
organically sourced full spectrum hemp CBD products on a pre-order
basis in the UK.
The Company is launching three initial
organically sourced, whole plant Hemp CBD rich oils in product and
tincture formats that maintain a full spectrum of secondary
cannabinoids, terpene profiles and flavonoids for wellbeing. The
company plans to launch several exclusive formulations of its
Leefylyfe™ branded products in 2019 and plans to extend sales to
the rest of Europe.
Pending the confirmation of the Farm Bill, which
was recently approved by the US Senate, the Company plans to
conduct a full launch if its new brand in the US, which is expected
to be powered by its trusted Bioganix® brand of nutraceutical and
skin care products.
“The entire Relevium team is proud and excited
to launch LeefyLyfe™ on a pre-order basis. Our product strategy is
to source locally in Europe, from GMP and Certified Organic
producers, a Hemp product that is natural and rich in cannabinoids
while respecting the THC threshold that is legally acceptable in
the region”. Sated Aurelio Useche, CEO.
“The launch of LeefyLyfe™ is consistent with our
focus on creating new revenue streams,
diversifying the product offering and continuing to elevate our
trusted brands. The company is actively integrating
Phyto-cannabinoids into its OTC business to provide bring the
natural goodness of Hemp to its portfolio and trusted Health and
Wellness products” stated Abis Hussain, Chief Marketing
Officer.
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operations of brands and businesses in
the Health and Wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products.
Relevium operates through two wholly-owned
subsidiaries:
BGX E-Health LLC (BGX): Based
in Orlando, Florida, BGX markets dietary supplements,
nutraceuticals, sports nutrition and cosmeceuticals primarily
through its Bioganix® brand portfolio in the US and Europe.
Relevium’s brands such as Bioganix® are sold at some of the world’s
largest retailers including such as Walmart.com and Amazon.com.
The Company’s strategy for growing its brands
includes expanding its product offering, adding new distribution
channels and developing partnerships that add value through
exclusive ingredients. BGX is currently testing a complete line of
dietary supplements derived from Cannabis with an initial focus on
hemp derived, whole plant organic extract rich in CBD
(cannabidiol). The product line will be marketed through its brand
LeefyLyfe® and will be sold first in Europe and then North America.
The Company uses cannabinoids and ingredients that have achieved
GRAS status (generally accepted as safe) to create brands that are
sold via wholesale channels, retail channels and online
distribution.
Biocannabix Health Corporation
(BCX): Based in Montreal, Quebec, BCX is an
entrepreneurial venture to establish a vertically integrated
medical cannabis company in the Nutraceutical space. Located in the
city of Saint Laurent, the Company is in the process of licensing
and retrofitting a facility that will host a genetically focused
cannabis growth, extraction, formulation, research and development
and encapsulation of proprietary Nutraceutical and Medical
products.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
This release includes certain statements and
information that may constitute forward-looking information within
the meaning of applicable Canadian securities laws. All statements
in this news release, other than statements of historical facts,
including statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, including the
timing and completion of the proposed acquisitions, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", "would" or "occur". Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including the assumptions that the Company
will be able to apply for and ultimately obtain an ACMPR license,
the proposed business of Biocannabix will develop as anticipated,
that the Company will raise sufficient funds to develop the
Biocannabix business, and that the Company will obtain all
requisite regulatory approvals. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information. Important factors that
may cause actual results to vary, include, without limitation, the
risk that the proposed business developments may not occur as
planned; the timing and receipt of requisite approvals and failure
to raise enough funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio UsechePresident and CEO
For more information about this press
release:
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.com Website: www.releviumtechnologies.com
Like us on FacebookFollow us on TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Apr 2023 to Apr 2024